



Genomic Health, Inc.
Investor Relations Department
301 Penobscot Dr.
Redwood City, CA 94063
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: GHDX

| | |
|---------------|----------------------------|
| Last Trade: | 33.56 |
| Trade Time: | 4:00 PM ET Oct 18, 2017 |
| Change: | 0.00 (0.000%) |
| Day Range | N/A - N/A |
| 52-Week Range | 26.37 - 33.97 |
| Volume | N/A |


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Sep 13, 2017*
[Genomic Health and Biocartis Announce Agreement to Develop an Idylla™ IVD Oncotype DX® Breast Cancer Test to Broaden Global Patient Access](#)
- Sep 11, 2017*
[Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017](#)
- Aug 31, 2017*
[Genomic Health Continues to Pioneer Genomic-based Cancer Diagnostics with Multiple Presentations at ESMO 2017 Congress](#)
- Aug 30, 2017*
[Genomic Health to Present at the 2017 Wells Fargo Healthcare Conference](#)
- Aug 24, 2017*
[Medicare Establishes Final Local Coverage Determination \(LCD\) for Use of the Oncotype DX® Genomic Prostate Score™ Test in Patients with Favorable Intermediate-risk Prostate Cancer Effective October 9, 2017](#)

Financials & Filings [\[View all \]](#)

- Mar 15, 2017*
[Annual Report \(10-K\)](#)
- Apr 28, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Aug 4, 2017*
[Quarterly Report \(10-Q\)](#)
- May 10, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 4, 2016*
[Quarterly Report \(10-Q\)](#)